FGFR3 and central nervous system cancer: Patients younger than 40 years of age diagnosed with an FGFR3-TACC3 glioma showed a significantly better progression-free survival (PFS) and overall survival (OS) compared to non-FGFR3-TACC3-fused gliomas.